Prognostic Value of IDH-1, PTEN and EGFR Expression in High Grade Gliomas

Basit Öğe Kaydı
dc.contributor.authorAktan, Meryem
dc.contributor.authorFindik, Sidika
dc.contributor.authorKanyilmaz, Gul
dc.contributor.authorYavuz, Berrin Benli
dc.contributor.authorKoc, Mehmet
dc.date.accessioned2024-02-23T14:40:52Z
dc.date.available2024-02-23T14:40:52Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractGliomas are the most common primary brain tumors in adults. Despite advances in modem diagnostic procedures and therapies, the prognosis is still poor. To improve survival and the knowledge about the biological and clinical presentation of gliomas, more individualised and targeted treatments are needed. The aim of this study was to correlate the immunostaining patterns of isocitrate dehydrogenase-1 (IDH-1), phosphatase and tensin homolog (PTEN) and epidermal growth factor (EGFR) with progression-free survival (PFS) and overall survival (OS) in high grade gliomas patients. We analized 60 high grade gliomas who underwent surgery and standard chemoradiotherapy. Immunohistochemical methods were used to classify the IDH-1 gene mutation presence, staining patterns of PTEN and EGFR in tumor samples of the diagnosis. Median follow-up time was 18.9 months. There was significant relation between IDH-1 mutation and OS. Median OS was 37.9 months for patients with IDH-1 mutation, 12.4 months for patients with no mutation (p< 0.001). Median PFS was 29.8 months for patients with no IDH-1 mutation and 70.4 months for patients with IDH-1 mutation (p= 0.03). There was no significant relation between PTEN and EGFR immunopattern and OS or PFS in univariate analysis. However, there was significant relation between immunoreactivity of PTEN and OS (p= 0.03), immunointensity of PTEN and OS (p= 0.02) in multivariate analysis. In conclusion, the relationship between EGFR mutation and OS and PFS can also be demonstrated by studies with more patients.en_US
dc.identifier.doi10.4999/uhod.192908
dc.identifier.endpage116en_US
dc.identifier.issn1306-133X
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85071362612en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage108en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.192908
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16621
dc.identifier.volume29en_US
dc.identifier.wosWOS:000473332100007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGliomaen_US
dc.subjectIdhen_US
dc.subjectEgfren_US
dc.subjectPtenen_US
dc.titlePrognostic Value of IDH-1, PTEN and EGFR Expression in High Grade Gliomasen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu